EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance

Yutao Chen, Anni Lu, Zhangli Hu, Jinyao Li, Jun Lu

Cancer Letters · 2024-09 · 599 · 217146

DOI: 10.1016/j.canlet.2024.217146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-09. Verfasst von Yutao Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Auckland Bioengineering Institute, University of Auckland, Auckland, 1142, New Zealand. Hauptthemen laut MEDLINE: Receptor, ErbB-3, Drug Resistance, Neoplasm, Neoplasms, Signal Transduction. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Society of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor-3 (ERBB3) is a member of the ERBB receptor tyrosine kinases (RTKs) and is expressed in many malignancies. Along with other ERBB receptors, ERBB3 is associated with regulating normal cell proliferation, apoptosis, differentiation, and survival, and has received increased research attention for its involvement in cancer therapies. ERBB3 expression or co-expression levels have been investigated as predictive factors for cancer prognosis and drug sensitivity. Additionally, the association between the elevated expression of ERBB3 and treatment failure in cancer therapy further established ERBB3-targeting therapy as a crucial therapeutic approach. This review delves into the molecular mechanisms of ERBB3-driven resistance to targeted therapeutics against ERBB2 and EGFR and other signal transduction inhibitors, endocrine therapy, chemotherapy, and radiotherapy. Using preclinical and clinical evidence, we synthesise and explicate how various aspects of aberrant ERBB3 activities-such as compensatory activation, signal crosstalk interactions, dysregulation in the endocytic pathway, mutations, ligand-independent activation, intrinsic kinase activity, and homodimerisation-can lead to resistance development and/or treatment failures. Several ERBB3-directed monoclonal antibodies, bispecific antibodies, and the emerging antibody-drug conjugate demonstrate encouraging clinical outcomes for improving therapeutic efficacy and overcoming resistance, especially when combined with other anti-cancer approaches. More research efforts are needed to identify appropriate biomarkers tailored for ERBB3-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, ErbB-3Drug Resistance, NeoplasmNeoplasmsSignal TransductionHumansMolecular Targeted TherapyAntineoplastic AgentsAnimalsProtein Kinase Inhibitors

Stichwörter der Autor:innen

CancerCancer therapyCell signallingERBB3MechanismResistance

Substanzen

Receptor, ErbB-3ERBB3 protein, humanAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Auckland Bioengineering Institute, University of Auckland, Auckland, 1142, New Zealand.
  • Pinehurst School, Albany, Auckland, New Zealand.
  • College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, China.
  • College of Life Sciences, Xijiang University, Urumqi, China.
  • Auckland Bioengineering Institute, University of Auckland, Auckland, 1142, New Zealand; College of Food Engineering and Nutrition Sciences, Shaanxi Normal University, Xi'an, 710119, Shaanxi Province, China; College of F…

Förderung

  • Royal Society of New Zealand

Zitieren

APA

Chen, Y., Lu, A., Hu, Z., Li, J., & Lu, J. (2024). ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance. Cancer Letters, 599, 217146. https://doi.org/10.1016/j.canlet.2024.217146

Vancouver

Chen Y, Lu A, Hu Z, Li J, Lu J. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance. Cancer Letters. 2024;599:217146. doi:10.1016/j.canlet.2024.217146

BibTeX
@article{Chen2024,
  author = {Chen, Yutao and Lu, Anni and Hu, Zhangli and Li, Jinyao and Lu, Jun},
  title = {ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance},
  journal = {Cancer Letters},
  year = {2024},
  volume = {599},
  pages = {217146},
  doi = {10.1016/j.canlet.2024.217146}
}
Kostenlos starten →